Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MK-8666 · 1 trial · 1 indication
Blood glucose was measured on a fasting basis (collected after an 8-hour fast). Blood was collected on Day -1 (pre-planned dose), predose on Days 1, 3, 7, and 14, and 24h postdose Day 14 (Day 15). The baseline measurement was computed as the average of the Day -1 and predose Day 1 measurements. FPG is expressed as mg/dL. This change from baseline reflects values for Day 15 FPG minus Day 0 FPG values.
An adverse event (AE) is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.
An adverse event (AE) is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.
| Arm | Type | Description |
|---|---|---|
| MK-8666 50 mg | EXPERIMENTAL | MK-8666, 50 mg, oral, once a day (QD) for Days 1 to 14. |
| MK-8666 150 mg | EXPERIMENTAL | MK-8666, 150 mg, oral, QD, for Days 1 to 14 |
| MK-8666 500 mg | EXPERIMENTAL | MK-8666, 500 mg, oral, QD for Days 1 to 14 |
| Placebo | PLACEBO_COMPARATOR | Placebo, oral, QD for Days 1 to 14 |
| Name | Type | Description |
|---|---|---|
| MK-8666 | DRUG | MK-8666, capsules, oral, QD, Days 1 to 14 |
| Placebo | DRUG | Placebo, capsules, oral, QD, Days 1 to 14 |
Inclusion Criteria: * If female, must be either postmenopausal or surgically sterile * A Body Mass Index (BMI) ≥18 kg/m\^2 to ≤40 kg/m\^2, inclusive. * A diagnosis of T2DM * Drug naïve or is being treated with no more than 2 oral antihyperglycemic agents (thiazolidenediones are excluded) * Judged t...
MK-8666 is an investigational small molecule being developed for the treatment of Type 2 Diabetes Mellitus. It is currently in Phase 1 clinical development, meaning it has not yet been approved by regulatory authorities and is still being studied for safety and efficacy.
MK-8666 is being developed by Merck & Company, Inc., a pharmaceutical company traded on the New York Stock Exchange under the ticker symbol MRK. The drug is in Phase 1 clinical development for Type 2 Diabetes Mellitus.
MK-8666 is in Phase 1 clinical development. It is an investigational drug for Type 2 Diabetes Mellitus and has not been approved by regulatory authorities. One Phase 1 clinical trial has been completed, and the drug is not currently in any active trials.
MK-8666 has been studied in one completed Phase 1 clinical trial, identified as NCT01971554. This trial evaluated the safety, tolerability, pharmacodynamics, and pharmacokinetics of MK-8666 in participants with Type 2 Diabetes Mellitus. The trial enrolled 63 participants and was randomized, double-blind, and placebo-controlled.
No alternative names for MK-8666 have been disclosed. The drug is identified by its development code MK-8666 and is being studied under the clinical trial identifier NCT01971554 for Type 2 Diabetes Mellitus.